Covagen Adds Baxter Ventures as Investor - KFVS12 News & Weather Cape Girardeau, Carbondale, Poplar Bluff

Covagen Adds Baxter Ventures as Investor

  • SPONSORED BY SOUTHEAST HEALTHMore>>

  • BJC changes charity care standards

    BJC changes charity care standards

    Sunday, April 20 2014 1:01 PM EDT2014-04-20 17:01:10 GMT
    Charity care has long been a core mission of BJC HealthCare, but the St. Louis area's largest employer is cutting back amid increasing financial pressures.
    Charity care has long been a core mission of BJC HealthCare, but the St. Louis area's largest employer is cutting back amid increasing financial pressures.
  • Clock ticking for states to adopt health exchanges

    Clock ticking for states to adopt health exchanges

    Friday, April 18 2014 2:39 PM EDT2014-04-18 18:39:20 GMT
    More than 30 states that defaulted to the federal government to run their health insurance markets under President Barack Obama's health care law must decide if they want to take a crack at it themselves. Time...
    More than 30 states that defaulted to the federal government to run their health insurance markets under President Barack Obama's health care law must decide if they want to take a crack at it themselves. Time is...
  • Blood test aims to predict breast cancer's return

    Blood test aims to predict breast cancer's return

    A new blood test may one day help predict the recurrence of breast cancer and also a woman's response to breast cancer treatment, researchers report.
    A new blood test may one day help predict the recurrence of breast cancer and also a woman's response to breast cancer treatment, researchers report.

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Covagen

Proceeds Bring Series B to CHF 44.9 Million

Anti-TNF/IL-17A Bispecific COVA322 Enters Clinic in Early 2014

ZURICH-SCHLIEREN, Switzerland, Feb. 19, 2014 /PRNewswire/ -- Covagen today announced it has added Baxter Ventures as an investor in its Series B financing round raising the total to CHF 44.9 million. The Series B includes an option for all existing investors to invest an additional CHF 14 million in the future potentially increasing the total amount of this financing round to CHF 58.9 million.

The additional financing will primarily support the clinical development of Covagen's lead FynomAb® COVA322, a bispecific TNF/IL-17A inhibitor for the treatment of rheumatoid arthritis, psoriatic arthritis and other inflammatory diseases. COVA322 has a novel mechanism of action not accessible with monoclonal antibodies and is expected to enter clinical trials in early 2014.

"Baxter's investment in our Series B round represents further validation that Covagen's bispecific FynomAb technology is uniquely capable of improving the treatment of cancer and inflammatory diseases," said Julian Bertschinger, Ph.D., chief executive officer of Covagen. "Adding an additional U.S. investor with the breadth and experience of Baxter Ventures will allow us to continue to advance towards our goal of bringing our lead FynomAb COVA322 through proof-of-concept in the clinic and strengthen our discovery programs in oncology."

Geeta Vemuri, vice president and head of Baxter Ventures added, "Covagen's bispecific FynomAb technology and highly capable management team made this an attractive investment for Baxter. The unique capability of FynomAbs to access new biology and novel modes-of-action offers the potential to improve the lives of patients suffering from cancer and inflammatory diseases."

About Baxter Ventures
Baxter Ventures is a venture initiative established in 2011 by Baxter International Inc. to invest in companies with innovative technologies, products and therapies with the ability to improve patient care globally and maximize value for investors and entrepreneurs. Baxter International Inc. is a global, diversified healthcare company that applies a unique combination of expertise in biotechnology, medical devices and pharmaceuticals to create products that advance patient care worldwide.

About Covagen
Covagen develops bispecific FynomAbs by fusing its human Fynomer binding proteins to antibodies resulting in therapeutics with novel modes-of-action and enhanced efficacy in the treatment of inflammatory diseases and cancer. Fynomers are small binding proteins that can be engineered to bind an antigen of interest. The ability to fuse Fynomers to multiple sites on an antibody allows Covagen to create FynomAbs with tailored architectures to maximize efficacy. Covagen is a privately held Swiss Biotech company with an internal lead bispecific anti-TNF/IL-17A FynomAb moving towards first-in-human studies in early 2014. In 2012, Covagen entered into a strategic alliance, which was recently expanded, with Mitsubishi Tanabe Pharma Corporation for the development of bispecific FynomAbs.

For more information please visit www.covagen.com

Corporate Contact:

Media Contacts:

Elias Papatheodorou

Matt Middleman, M.D.

Chief Business Officer

Tony Russo, Ph.D.

Tel: +41 (0) 44 732 46 60

Russo Partners

info@covagen.com

Tel: +1212 845 4272


Tel: +1212 845 4251


matt.middleman@russopartnersllc.com


tony.russo@russopartnersllc.com

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

310 Broadway
Cape Girardeau, MO 63701

FCC Public File
publicfile@kfvs12.com
573-335-1212
EEO Report
Closed Captioning

All content © Copyright 2000 - 2014 Worldnow and KFVS12. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.